Skip to main content
SpringerLink
Log in

Standardized sublingual allergen extract solution (Staloral®): a guide to its use as allergen-specific immunotherapy

  • Adis Drug Clinical Q&A
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

Abstract

Sublingual administration of standardized allergen-specific immunotherapy (AIT) is a valuable option in the treatment of aeroallergen-induced allergies. Staloral® is a solution containing standardized extracts of allergens (e.g. house-dust mites, pollens, moulds or animal danders) at different and increasing concentrations. It is administered under the tongue via a pre-dosed actuator, held for 2 min and then swallowed. In clinical trials in children and/or adults with allergic symptoms induced by house-dust mites or various types of grass, weed or tree pollens, AIT with Staloral® significantly reduced allergy symptoms and the use of symptomatic rescue medications, and was well tolerated.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Brozek JL, Bousquet J, Baena-Cagnani CE, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 revision. J Allergy Clin Immunol. 2010;126(3):466–76.

    Article  PubMed  Google Scholar 

  2. Burks AW, Calderon MA, Casale T, et al. Update on allergy immunotherapy: American Academy of Allergy, Asthma & Immunology/European Academy of Allergy and Clinical Immunology/PRACTALL consensus report. J Allergy Clin Immunol. 2013;131(5):1288–96.

    Article  PubMed  Google Scholar 

  3. Canonica GW, Cox L, Pawankar R, et al. Sublingual immunotherapy: World Allergy Organization position paper 2013 update. World Allergy Organ J. 2014;7(1):6. doi:10.1186/1939-4551-7-6.

    Article  PubMed Central  PubMed  Google Scholar 

  4. Zuberbier T, Bachert C, Bousquet PJ, et al. GA2LEN/EAACI pocket guide for allergen-specific immunotherapy for allergic rhinitis and asthma. Allergy. 2010;65(12):1525–30.

    Article  CAS  PubMed  Google Scholar 

  5. Braido F, Arcadipane F, Marugo F, et al. Allergic rhinitis: current options and future perspectives. Curr Opin Allergy Clin Immunol. 2014;14(2):168–76.

    Article  CAS  PubMed  Google Scholar 

  6. Brehler R, Klimek L, Kopp MV, et al. Specific immunotherapy-indications and mode of action. Dtsch Arztebl Int. 2013;110(9):148–58.

    PubMed Central  PubMed  Google Scholar 

  7. Compalati E, Passalacqua G, Bonini M, et al. The efficacy of sublingual immunotherapy for house dust mites respiratory allergy: results of a GA2LEN meta-analysis. Allergy. 2009;64(11):1570–9.

    Article  CAS  PubMed  Google Scholar 

  8. Calderon MA, Penago M, Sheikh A, et al. Sublingual immunotherapy for treating allergic conjunctivitis. Cochrane Database Syst Rev. 2011;6(7):CD007685.

    Google Scholar 

  9. Radulovic S, Calderon MA, Wilson D, et al. Sublingual immunotherapy for allergic rhinitis. Cochrane Database Syst Rev. 2010;12:CD002893.

    PubMed  Google Scholar 

  10. Penagos M, Passalacqua G, Compalati E, et al. Metaanalysis of the efficacy of sublingual immunotherapy in the treatment of allergic asthma in pediatric patients, 3 to 18 years of age. Chest. 2008;133(3):599–609.

    Article  CAS  PubMed  Google Scholar 

  11. Olaguíbel JM, Álvarez Puebla MJ. Efficacy of sublingual allergen vaccination for respiratory allergy in children: conclusions from one meta-analysis. J Investig Allergol Clin Immunol. 2005;15(1):9–16.

    PubMed  Google Scholar 

  12. Incorvaia C, Di Rienzo A, Celani C, et al. Treating allergic rhinitis by sublingual immunotherapy: a review. Ann Ist Super Sanita. 2012;48(2):172–6.

    Article  CAS  PubMed  Google Scholar 

  13. Larenas-Linnemann D. Sublingual immunotherapy in children: complete and updated review supporting evidence of effect. Curr Opin Allergy Clin Immunol. 2009;9(2):168–76.

    Article  PubMed  Google Scholar 

  14. Lin SY, Erekosima N, Kim JM, et al. Sublingual immunotherapy for the treatment of allergic rhinoconjunctivitis and asthma: a systematic review. JAMA. 2013;309(12):1278–88.

    Article  CAS  PubMed  Google Scholar 

  15. Sieber J, Shah-Hosseini K, Mösges R. Specific immunotherapy for allergic rhinitis to grass and tree pollens in daily medical practice: symptom load with sublingual immunotherapy compared to subcutaneous immunotherapy. Ann Med. 2011;43(6):418–24.

    Article  CAS  PubMed  Google Scholar 

  16. Frati F, Incorvaia C, David M, et al. Requirements for acquiring a high-quality house dust mite extract for allergen immunotherapy. Drug Des Devel Ther. 2012;6:117–23.

    PubMed Central  PubMed  Google Scholar 

  17. Frati F, Scurati S, Puccinelli P, et al. Development of a sublingual allergy vaccine for grass pollinosis. Drug Des Devel Ther. 2010;4:99–105.

    PubMed Central  PubMed  Google Scholar 

  18. Frati F, Scurati S, Puccinelli P, et al. Development of an allergen extract for sublingual immunotherapy: evaluation of Staloral. Expert Opin Biol Ther. 2009;9(9):1207–15.

    Article  CAS  PubMed  Google Scholar 

  19. Staloral sublingual solution of allergen extract of birch pollen: summary of prescribing information [in German]. Anthony: Stallergenes S.A.; 2013.

  20. Fujita JH, Soyka MB, Akdis M, et al. Mechanisms of allergen-specific immunotherapy. Clin Transl Allergy. 2012;2(1):2. doi:10.1186/2045-7022-2-2.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  21. Moingeon P. Update on immune mechanisms associated with sublingual immunotherapy: practical implications for the clinician. J Allergy Clin Immunol Pract. 2013;1(3):228–41.

    Article  PubMed  Google Scholar 

  22. Calderón MA, Simons FE, Malling HJ, et al. Sublingual allergen immunotherapy: mode of action and its relationship with the safety profile. Allergy. 2012;67(3):302–11.

    Article  PubMed  Google Scholar 

  23. Batard T, Nony E, Hrabina M, et al. Advances in the quantification of relevant allergens in allergenic extracts. Eur Ann Allergy Clin Immunol. 2013;45(Suppl 2):33–7.

    Google Scholar 

  24. Bousquet J, Scheinmann P, Guinnepain MT, et al. Sublingual-swallow immunotherapy (SLIT) in patients with asthma due to house-dust mites: a double-blind, placebo-controlled study. Allergy. 1999;54(3):249–60.

    Article  CAS  PubMed  Google Scholar 

  25. Wang L, Yin J, Fadel R, et al. House dust mite sublingual immunotherapy is safe and appears to be effective in moderate, peristent asthma. Allergy. 2014;69(9):1181–8.

    Article  CAS  PubMed  Google Scholar 

  26. Guez S, Vatrinet C, Fadel R, et al. House-dust-mite sublingual-swallow immunotherapy (SLIT) in perennial rhinitis: a double-blind, placebo-controlled study. Allergy. 2000;55(4):369–75.

    Article  CAS  PubMed  Google Scholar 

  27. Bozek A, Ignasiak B, Filipowska B, et al. House dust mite sublingual immunotherapy: a double-blind, placebo-controlled study in elderly patients with allergic rhinitis. Clin Exp Allergy. 2013;43(2):242–8.

    Article  CAS  PubMed  Google Scholar 

  28. Mortemousque B, Bertel F, De Casamayor J, et al. House-dust mite sublingual-swallow immunotherapy in perennial conjunctivitis: a double-blind, placebo-controlled study. Clin Exp Allergy. 2003;33(4):464–9.

    Article  CAS  PubMed  Google Scholar 

  29. Trebuchon F, David M, Demoly P. Medical management and sublingual immunotherapy practices in patients with house dust mite-induced respiratory allergy: a retrospective, observational study. Int J Immunopathol Pharmacol. 2012;25(1):193–206.

    CAS  PubMed  Google Scholar 

  30. Trebuchon F, Lhéritier-Barrand M, David M, et al. Characteristics and management of sublingual allergen immunotherapy in children with allergic rhinitis and asthma induced by house dust mite allergens. Clin Transl Allergy. 2014;4:15. doi:10.1186/2045-7022-4-15.

    Article  PubMed Central  PubMed  Google Scholar 

  31. Nuhoglu Y, Ozumut SS, Ozdemir C, et al. Sublingual immunotherapy to house dust mite in pediatric patients with allergic rhinitis and asthma: a retrospective analysis of clinical course over a 3-year follow-up period. J Investig Allergol Clin Immunol. 2007;17(6):375–8.

    CAS  PubMed  Google Scholar 

  32. Ferrés J, Justicia JL, García MP, et al. Efficacy of high-dose sublingual immunotherapy in children allergic to house dust mites in real-life clinical practice. Allergol Immunopathol (Madr). 2011;39(3):122–7.

    Article  PubMed  Google Scholar 

  33. Park IH, Hong SM, Lee HM. Efficacy and safety of sublingual immunotherapy in Asian children. Int J Pediatr Otorhinolaryngol. 2012;76(12):1761–6.

    Article  PubMed  Google Scholar 

  34. Ozdemir C, Yazi C, Cocmen I, et al. Efficacy of long-term sublingual immunotherapy as an adjunct to pharmacotherapy in house dust mite-allergic children with asthma. Pediatr Allergy Immunol. 2007;18:508–15.

    Article  PubMed  Google Scholar 

  35. Sabbah A, Hassoun S, Le Sellin J, et al. A double-blind, placebo-controlled trial by the sublingual route of immunotherapy with a standardized grass pollen extract. Allergy. 1994;49(5):309–13.

    Article  CAS  PubMed  Google Scholar 

  36. Clavel R, Bousquet J, André C. Clinical efficacy of sublingual-swall immunotherapy: a double-blind, placebo-controlled trial of a standardized five-grass-pollen extract in rhinitis. Allergy. 1998;53(5):493–8.

    Article  CAS  PubMed  Google Scholar 

  37. Stelmach I, Kaluzińska-Parzyszek I, Jerzynska J, et al. Comparative effect of pre-coseasonal and continuous grass sublingual immunotherapy in children. Allergy. 2012;67(3):312–20.

    Article  CAS  PubMed  Google Scholar 

  38. Stelmach I, Kaczmarek-Woźniak J, Majak P, et al. Efficacy and safety of high-doses sublingual immunotherapy in ultra-rush scheme in children allergic to grass pollen. Clin Exp Allergy. 2009;39(3):401–8.

    Article  CAS  PubMed  Google Scholar 

  39. Ott H, Sieber J, Brehler R, et al. Efficacy of grass pollen sublingual immunotherapy for three consecutive seasons and after cessation of treatment: the ECRIT study. Allergy. 2009;64(9):1394–401.

    Article  CAS  PubMed  Google Scholar 

  40. Bozek A, Kolodziejczyk K, Warkocka-Szoltysek B, et al. Grass pollen sublingual immunotherapy: a double-blind, placebo-controlled study in elderly patients with seasonal allergic rhinitis. Am J Rhinol Allergy. 2014;28(5):423–7.

    Article  PubMed  Google Scholar 

  41. La Rosa M, Ranno C, André C, et al. Double-blind placebo-controlled evaluation of sublingual-swallow immunotherapy with standardized Parietaria judaica extract in children with allergic rhinoconjunctivitis. J Allergy Clin Immunol. 1999;104(2 Pt 1):425–32.

    Article  PubMed  Google Scholar 

  42. Bowen T, Greenbaum J, Charbonneau Y, et al. Canadian trial of sublingual swallow immunotherapy for ragweed rhinoconjunctivitis. Ann Allergy Asthma Immunol. 2004;93(5):425–30.

    Article  PubMed  Google Scholar 

  43. Worm M, Rak S, de Blay F, et al. Sustained efficacy and safety of a 300IR daily dose of a sublingual solution of birch pollen allergen extract in adults with allergic rhinoconjunctivitis: results of a double-blind, placebo-controlled study. Clin Transl Allergy. 2014;4(1):7. doi:10.1186/2045-7022-4-7.

    Article  PubMed Central  PubMed  Google Scholar 

  44. Vourdas D, Syrigou E, Potamianou P, et al. Double-blind, placebo-controlled evaluation of sublingual immunotherapy with standardized olive pollen extract in pediatric patients with allergic rhinoconjunctivitis and mild asthma due to olive pollen sensitization. Allergy. 1998;53(7):662–72.

    Article  CAS  PubMed  Google Scholar 

  45. Di Rienzo V, Pucci S, D’Alò S, et al. Effects of high-dose sublingual immunotherapy on quality of life in patients with cypress-induced rhinitis: a placebo-controlled study. Clin Exp Allergy Rev. 2006;6:67–70.

    Article  Google Scholar 

  46. Vervloet D, Birnbaum J, Laurent P, et al. Safety and efficacy of Juniperus ashei sublingual-swallow ultra-rush pollen immunotherapy in cypress rhinoconjunctivitis: a double-blind, placebo-controlled study. Int Arch Allergy Immunol. 2007;142(3):239–46.

    Article  CAS  PubMed  Google Scholar 

  47. Hadler M, Karagiannis E, Shah-Hosseini K, et. al. Effectiveness and tolerability of a 2-year sublingual allergen immunotherapy in routine medical practice in birch pollen allergic patients [abstract no. 1326]. Allergy. 2013;68(Suppl 97):483. Plus poster presented at the European Academy of Allergy and Clinical Immunology and World Allergy Organization World Allergy and Asthma Congress, 22–26 June 2013, Milan.

  48. Lyseng-Williamson KA. Sublingual five-grass pollen tablets (Oralair®): a guide to their use as allergen immunotherapy for grass pollen-induced allergic rhinoconjunctivitis. Drug Ther Perspect. 2014;30(6):200–8.

    Article  Google Scholar 

  49. Karagiannis E, Shah-Hosseini K, Hadler M, et al. Effectiveness and tolerability of a 2-year sublingual allergen immunotherapy (AIT) in children and adolescents allergic rhinoconjunctivitis caused by birch pollen [abstract no. 423]. In: European Academy of Allergy and Clinical Immunology 2014 Annual Congress, 7–11 June 2014, Copenhagen.

  50. Hadler M, Karagiannis E, Shah-Hosseini K, et. al. Polyallergic patients treated in daily medical practice: results from a 2-year sublingual allergen immunotherapy study [abstract no. 1535]. Allergy. 2013;68(Suppl 97):548. Plus poster presented at the European Academy of Allergy and Clinical Immunology and World Allergy Organization World Allergy and Asthma Congress, 22–26 June 2013, Milan.

  51. Hadler M, Karagiannis E, Shah-Hosseini K, et. al. Full symptom control in patients with allergic rhinoconjunctivitis induced by birch pollen treated with sublingual allergen immunotherapy (AIT) in real-life medical practice [abstract no. 1416]. In: European Academy of Allergy and Clinical Immunology 2014 Annual Congress, 7–11 June 2014, Copenhagen.

  52. Sieber J, Neis M, Brehler R, et al. Increasing long-term safety of seasonal grass pollen sublingual immunotherapy: the ECRIT study. Expert Opin Drug Saf. 2012;11(1):7–13.

    Article  PubMed  Google Scholar 

  53. Roger A, Justicia JL, Navarro LA, et al. Observational study of the safety of an ultra-rush sublingual immunotherapy regimen to treat rhinitis due to house dust mites. Int Arch Allergy Immunol. 2011;154(1):69–75.

    Article  PubMed  Google Scholar 

  54. Seidenberg J, Pajno GB, Bauer CP, et al. Safety and tolerability of seasonal ultra-rush, high-dose sublingual-swallow immunotherapy in allergic rhinitis to grass and tree pollens: an observational study in 193 children and adolescents. J Investig Allergol Clin Immunol. 2009;19(2):125–31.

    CAS  PubMed  Google Scholar 

  55. Ciprandi G, Cadario G, Di Gioacchino M, et al. Sublingual immunotherapy in polysensitized allergic patients with rhinitis and/or asthma: allergist choices and treatment efficacy. J Biol Regul Homeost Agents. 2009;23(3):165–71.

    CAS  PubMed  Google Scholar 

  56. Ciprandi G, Cadario G, Di Gioacchino GM, et al. Sublingual immunotherapy in children with allergic polysensitization. Allergy Asthma Proc. 2010;31(3):227–31.

    Article  PubMed  Google Scholar 

  57. Bozek A, Filipowska-Gronska A, Warkocka-Szoltysek B, et al. Effectiveness and safety of immunotherapy in patients over 50 years of age with grass pollen and birch allergy [abstract no. 1386]. Allergy. 2012;67(Suppl 96):520.

    Google Scholar 

  58. Irani C, Saleh RA, Jammal M, et al. High-dose sublingual immunotherapy in patients with uncontrolled allergic rhinitis sensitized to pollen: a real-life clinical study. Int Forum Allergy Rhinol. 2014;4(10):802–7.

  59. Ciprandi G, Cadario G, Valle C, et al. Sublingual immunotherapy in polysensitized patients: effect on quality of life. J Investig Allergol Clin Immunol. 2010;20(4):274–9.

    CAS  PubMed  Google Scholar 

  60. Hadler M, Schnitzer S, Schnitker J, et al. Treatment satisfaction with sublingual immunotherapy in a real-life setting [abstract no. 202]. World Allergy Organ J. 2012;5(Suppl 2):S67.

    Article  Google Scholar 

  61. Sieber J, De Geest S, Shah-Hosseini K, et al. Medication persistence with long-term, specific grass pollen immunotherapy measured by prescription renewal rates. Curr Med Res Opin. 2011;27(4):855–61.

    Article  CAS  PubMed  Google Scholar 

  62. Berto P, Bassi M, Incorvaia C, et al. Cost effectiveness of sublingual immunotherapy in children with allergic rhinitis and asthma. Eur Ann Allergy Clin Immunol. 2005;37(8):303–8.

    CAS  PubMed  Google Scholar 

  63. Berto P, Frati F, Incorvaia C, et al. Comparison of costs of sublingual immunotherapy and drug treatment in grass-pollen induced allergy: results from the SIMAP database study. Curr Med Res Opin. 2008;24(1):261–6.

    Article  PubMed  Google Scholar 

  64. Ariano R, Berto P, Incorvaia C, et al. Economic evaluation of sublingual immunotherapy vs. symptomatic treatment in allergic asthma. Ann Allergy Asthma Immunol. 2009;103(3):254–9.

    Article  PubMed  Google Scholar 

  65. Bielik J, Pruzinec P, Tor P. Clinical and pharmacoeconomic aspects of allergen immunotherapy in the Slovak Republic [abstract no. PRS14]. Value Health. 2012;15(7):A561–2.

    Article  Google Scholar 

Download references

Acknowledgments

The manuscript was reviewed by: F. Horak, Vienna Challenge Chamber Institute for Allergy Research, Vienna, Austria; C. Incorvaia, Allergy/Pulmonary Rehabilitation Unit, Istituti Clinici di Perfezionamento Hospital, Milan, Italy; U.Wahn, Department of Pediatric Pneumology and Immunology, Charité Medical University, Berlin, Germany.

Disclosure

The preparation of this review was not supported by any external funding. The author is a salaried employee of Adis/Springer. During the peer review process, the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from comments received were made by the author on the basis of scientific and editorial merit.

Author information

Authors and Affiliations

  1. Springer, Private Bag 65901, Mairangi Bay, North Shore, 0754, Auckland, New Zealand

    Katherine A. Lyseng-Williamson

Authors
  1. Katherine A. Lyseng-Williamson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Katherine A. Lyseng-Williamson.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lyseng-Williamson, K.A. Standardized sublingual allergen extract solution (Staloral®): a guide to its use as allergen-specific immunotherapy. Drugs Ther Perspect 30, 401–410 (2014). https://doi.org/10.1007/s40267-014-0165-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40267-014-0165-x

Keywords

Search

Navigation